We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bile Acid Profile in Severe Fibromyalgia Associated with Microbiome Changes

By LabMedica International staff writers
Posted on 01 Aug 2022

Fibromyalgia (FM) is a medical condition defined by the presence of chronic widespread pain, fatigue, waking unrefreshed, cognitive symptoms, lower abdominal pain or cramps, and depression. Other symptoms include insomnia and a general hypersensitivity.

The cause of fibromyalgia is unknown, but is believed to involve a combination of genetic and environmental factors. Environmental factors may include psychological stress, trauma, and certain infections. The pain appears to result from processes in the central nervous system and the condition is referred to as a "central sensitization syndrome.


Image: Altered serum bile acid profile in fibromyalgia is associated with specific gut microbiome changes and symptom severity (Photo courtesy of Blood Tests in London)
Image: Altered serum bile acid profile in fibromyalgia is associated with specific gut microbiome changes and symptom severity (Photo courtesy of Blood Tests in London)

Pain Medicine specialists at the McGill University Health Centre (Montreal, QC, Canada) and their Israeli colleagues characterized the gut microbiome and circulating bile acids in a cohort of 42 women with fibromyalgia and 42 healthy controls. They used 16S rRNA sequencing and targeted metabolomic approaches to find any differences.

Alterations in the relative abundance of several bacterial species known to metabolize bile acids were observed in women with fibromyalgia, accompanied by significant alterations in the serum concentration of secondary bile acids, including a marked depletion of α-muricholic acid. Statistical learning algorithms could accurately detect individuals with fibromyalgia using the concentration of these serum bile acids.

Serum α-muricholic acid was highly correlated with symptom severity, including pain intensity and fatigue. Taken together, these findings suggest serum bile acid alterations are implicated in nociplastic pain. The changes observed in the composition of the gut microbiota and the concentration of circulating secondary bile acids seems congruent with the phenotype of increased nociception and was quantitatively correlated with symptom severity.

Amir Minerbi MD, PhD, Attending Physician at Rambam Institute for Pain Medicine (Haifa, Israel), and an author of the study, said, “These findings are surprising and show a strong connection between the composition of the intestinal bacteria, the concentration of bile acids in the blood and the severity of the symptoms in people with fibromyalgia.”

The authors concluded that women with fibromyalgia show significant alterations in serum bile acids and gut bile-metabolizing bacteria. These alterations are correlated with syndrome symptom severity. The study was published originally published on May 19, 2022 in the journal Pain.

Related Links:
McGill University Health Centre 
Rambam Institute for Pain Medicine 


New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Silver Member
Oncology Molecular Diagnostic Test
BCR-ABL Dx ELITe MGB Kit
New
Chemistry Analyzer
MS100

Latest Clinical Chem. News

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability